| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Radium-223 |
| Brand | Xofigo® |
| Indication | For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It is for use in the hospital setting. |
| Assessment Process | |
| Rapid review commissioned | 28/11/2013 |
| Rapid review completed | 23/12/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 11/04/2014 |
| NCPE assessment completed | 12/12/2014 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE does not recommend reimbursement of radium-223 at the submitted price.
The HSE has approved reimbursement following confidential price negotiations December 2015.
